Last reviewed · How we verify

Xylocaine

AstraZeneca · FDA-approved active Small molecule ✓ Verified May 2026

Xylocaine is a Small molecule drug developed by AstraZeneca. It is currently FDA-approved. Also known as: lidocaine 2%, X, Bananenspray, Lidocaine spray.

Xylocaine, also known as lidocaine, is a local anesthetic of the amino amide type that works by blocking the sodium channel alpha subunit. It is used to treat various conditions, including pain during medical procedures, such as copper intrauterine device insertion, and is also used to treat ventricular tachycardia and ventricular fibrillation.

At a glance

Generic nameXylocaine
Also known aslidocaine 2%, X, Bananenspray, Lidocaine spray, XYLOCAINE IV INJECTION
SponsorAstraZeneca
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Xylocaine

What is Xylocaine?

Xylocaine is a Small molecule drug developed by AstraZeneca.

Who makes Xylocaine?

Xylocaine is developed and marketed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Xylocaine also known as anything else?

Xylocaine is also known as lidocaine 2%, X, Bananenspray, Lidocaine spray, XYLOCAINE IV INJECTION.

What development phase is Xylocaine in?

Xylocaine is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing